EQRx
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2024 |
---|---|---|---|---|
Revenues | - | - | - | 1.3m |
EBITDA | (250m) | (204m) | (518m) | - |
Profit | (250m) | (100m) | (169m) | - |
R&D budget | 224m | 118m | 228m | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$200m | Series A | ||
$500m | Series B | ||
$552m Valuation: $3.7b -14.6x EV/LTM EBITDA | SPAC IPO | ||
$1.2b Valuation: $3.7b -14.6x EV/LTM EBITDA | SPAC Private Placement | ||
* | N/A | Acquisition | |
Total Funding | $1.9b |
Recent News about EQRx
EditEQRx is a biotechnology company focused on developing and delivering innovative medicines at significantly lower prices. The company aims to address the high cost burden of healthcare by creating a catalog of new medicines that are more affordable and accessible. EQRx operates in the pharmaceutical and healthcare markets, targeting disease areas with the highest cost burdens on society. The business model revolves around leveraging cutting-edge innovation and strategic collaborations to produce high-quality, cost-effective treatments. EQRx generates revenue by bringing these affordable medicines to market, thereby increasing access to essential healthcare solutions for a broader population. The company's clients include healthcare providers, patients, and payers who benefit from reduced costs and improved access to new treatments. EQRx's mission is to transform the healthcare system by making it more sustainable and equitable through innovative and affordable medical solutions.
Keywords: biotechnology, affordable medicines, healthcare innovation, pharmaceutical, cost-effective treatments, strategic collaborations, disease burden, healthcare providers, patients, payers.